XCUR Looks 231.6% Overvalued on GF Value™
Exicure Inc (NASDAQ: XCUR) is issuing shares for a milestone payment related to a successful Phase 2 clinical trial, yet its stock appears significantly overvalued. The company has a GF Score™ of 32/100, reflecting weak profitability and financial strength, and its GF Value™ estimates …